A Phase II Study of Clinical Outcomes of 3-Week Cycles of Irinotecan and S-1 in Patients with Previously Untreated Metastatic Colorectal Cancer: Influence of theUGT1A1andCYP2A6Polymorphisms on Clinical Activity-Reference-Cited by-同舟云学术

A Phase II Study of Clinical Outcomes of 3-Week Cycles of Irinotecan and S-1 in Patients with Previously Untreated Metastatic Colorectal Cancer: Influence of theUGT1A1andCYP2A6Polymorphisms on Clinical Activity

Published:2012 Issue:5 Volume:82 Page:290-297
ISSN:1423-0232
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Choi Yoon Hee,Kim Tae Won,Kim Kyu-Pyo,Lee Sung Sook,Hong Yong Sang,Ryu Min-Hee,Lee Jae-Lyun,Chang Heung Moon,Ryoo Baek-Yeol,Kim Ho-Sook,Shin Jae-Gook,Kang Yoon-Koo

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Reference42 articles.

1. Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer

2. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer.

3. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

4. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma

5. Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of CYP2A6 Gene Polymorphism on the Efficacy and Safety of S-1 Therapy in Patients with Gastric Cancer: A Systematic Review and Meta-Analysis;Chemotherapy;2024-04-10

2. Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?;Frontiers in Pharmacology;2023-05-15

3. Association of UGT1A1*6 , UGT1A1*28 , or ABCC2 c.3972C>T genetic polymorphisms with irinotecan‐induced toxicity in Asian cancer patients: Meta‐analysis;Clinical and Translational Science;2022-05-31

4. A fatal myelosuppression, diarrhea and neurotoxicity induced by combination of irinotecan and tegafur-gimeracil-oteracil potassium in the treatment of colon cancer: a case report;Translational Cancer Research;2020-01

5. Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer;Anticancer Research;2018-03-28